



OPEN ACCESS

EDITED AND REVIEWED BY
Junmei Wang,
University of Pittsburgh, United States

*CORRESPONDENCE
Wenzhi Wu,
✉ wwzljy@163.com
Ren-ai Xu,
✉ xra@wmu.edu.cn

RECEIVED 13 September 2024
ACCEPTED 23 September 2024
PUBLISHED 27 September 2024

CITATION
Xia H, Xu X, Chen J, Wu H, Shen Y, Chen X,
Xu R-a and Wu W (2024) Corrigendum:
Inhibitory effects of calcium channel blockers
nisoldipine and nimodipine on ivacaftor
metabolism and their underlying mechanism.
Front. Pharmacol. 15:1495855.
doi: 10.3389/fphar.2024.1495855

COPYRIGHT
© 2024 Xia, Xu, Chen, Wu, Shen, Chen, Xu and
Wu. This is an open-access article distributed
under the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism

Hailun Xia, Xinhao Xu, Jie Chen, Hualu Wu, Yuxin Shen,
Xiaohai Chen, Ren-ai Xu* and Wenzhi Wu*

First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

KEYWORDS

cystic fibrosis, ivacaftor, nisoldipine, nimodipine, drug-drug interaction, pharmacokinetics

A Corrigendum on Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism

by Xia H, Xu X, Chen J, Wu H, Shen Y, Chen X, Xu R-a and Wu W (2024). *Front. Pharmacol.* 15:1403649. doi: 10.3389/fphar.2024.1403649

In the published article, there was an error in [Figure 7](#) as published. During the mapping process, the wrong unit of concentration value was used. Previous mapping used mg/mL as the unit of concentration for the X-value, which is inconsistent with the unit used for the figure, and is now converted to μM . The resulting K_i -values change from 0.17 and 0.30 to 3.26 and 5.87, respectively. The corrected [Figure 7](#) and its caption appear below.

In the published article, there was an error in [Table 2](#) as published. During the mapping process, the wrong unit of concentration value was used for Nimodipine. Previous mapping used mg/mL as the unit of concentration for the X-value, which is inconsistent with the unit used in the table, and is now converted to μM . The resulting K_i -values change from 0.17 and 0.30 to 3.26 and 5.87, respectively. The corrected [Table 2](#) and its caption appear below.

In the published article, there was an error. During the mapping process, the wrong unit of concentration value was used. Previous mapping used mg/mL as the unit of concentration for the X-value and is now converted to μM . The resulting K_i -values change from 0.17 and 0.30 to 3.26 and 5.87, respectively.

A correction has been made to **3 Results**, 3.3 *Nisoldipine and nimodipine inhibited ivacaftor metabolism in RLM and in HLM through different inhibitory mechanisms*. This sentence previously stated:

“The K_i values were 0.17 and 0.30, respectively ([Table 2](#)).”

The corrected sentence appears below:

“The K_i values were 3.26 and 5.87, respectively ([Table 2](#)).”

The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 7 Lineweaver-burk plot, secondary diagram of K_i inhibiting ivacaftor metabolism at different concentrations of nimodipine in RLM (A) and in HLM (B).

TABLE 2 The IC_{50} values and inhibitory effects of nisoldipine and nimodipine on ivacaftor metabolism in RLM and HLM.

Inhibitors		IC_{50} values (μM)	Inhibition type	K_i (μM)	αK_i (μM)	α
Nisoldipine	RLM	6.55	non-competitive inhibition and competitive inhibition	3.35	8.48	2.53
	HLM	9.10	non-competitive inhibition and competitive inhibition	3.92	35.40	9.03
Nimodipine	RLM	4.57	competitive inhibition	3.26		
	HLM	7.15	competitive inhibition	5.87		

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.